PTC Therapeutics, Inc. (PTCT) Operating income 2016–2025
PTC Therapeutics, Inc. (PTCT) annual operating income history from SEC filings — each fiscal year as reported.
$866.9MFY2025 · since FY2016: -$132.1M → $866.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $866.9M | +386.5% |
| FY2024 | -$302.6M | +31.2% |
| FY2023 | -$439.5M | +1.8% |
| FY2022 | -$447.4M | -19.5% |
| FY2021 | -$374.4M | +13.3% |
| FY2020 | -$431.8M | -79.0% |
| FY2019 | -$241.2M | -108.5% |
| FY2018 | -$115.7M | -79.9% |
| FY2017 | -$64.3M | +51.3% |
| FY2016 | -$132.1M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More PTCT financial trends
PTCT RevenuePTCT Net incomePTCT Net marginPTCT Gross profitPTCT Gross marginPTCT Operating marginPTCT Operating cash flowPTCT Free cash flowPTCT Capital expendituresPTCT Return on equityPTCT Stock buybacksPTCT Dividends paidPTCT Total assetsPTCT Total liabilitiesPTCT Shareholders’ equityPTCT overview →